ArticleDiscover oncology2026
Integrated single-cell and bulk transcriptomic analyses unveil a necroptosis-related prognostic model and its association with tumor microenvironment remodeling in gastric cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundNecroptosis has emerged as a critical regulator in tumor progression and therapeutic response, yet its prognostic significance and influence on the tumor microenvironment (TME) in gastric cancer (GC) remain poorly characterized. Therefore, it is needed to unveil the intricate relationship between GC and necroptosis.
methodsWe conducted an integrative analysis of bulk and single-cell data to delineate the prognostic landscape of necroptosis in GC. A necroptosis-related (NR) model was established using transcriptomic data from the TCGA cohort and validated in an external GEO cohort. To translate this model into clinical practice, a prognostic nomogram incorporating NR scores and clinical parameters was constructed. The molecular mechanisms underlying NR variations were investigated through stemness analysis, pathway enrichment, immune cell infiltration profiling, and intercellular communication networks.
resultsConsensus clustering analysis revealed pronounced heterogeneity in GC by stratifying patients into two survival-associated NR clusters (cluster 1 and cluster 2) with differences in TME characteristics. Employing machine learning approaches, a NR model was developed and validated, which demonstrated predictive ability for survival outcomes. Meanwhile, the nomogram demonstrated clinically relevant predictive accuracy, with time-dependent area under curve (AUC) values of 0.701 (1-year), 0.715 (3-year), and 0.753 (5-year). Notably, this NR model enabled robust stratification of GC patients into two distinct subgroups, both in bulk and single-cell datasets. Single-cell resolution analysis revealed patients with varying NR scores were characterized by aberrant enrichment of endothelial cells, epithelial cells, and fibroblasts, highlighting the profound impact of necroptosis on cellular composition within the TME.
conclusionsOur novel NR model deciphers the dynamic interplay between necroptosis and TME remodeling in GC, enabling robust patient stratification across both bulk and single-cell data and revealing a necroptosis-driven environment characterized by aberrant expansion of endothelial cells, epithelial cells, and fibroblasts. The clinically applicable nomogram offers a precision medicine framework for risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.